Unicycive Therapeutics faces securities litigation following investor complaint
Investors have initiated legal action against Unicycive Therapeutics alleging securities fraud. A deadline for lead plaintiff applications has been set for November.
Rosen Law Firm has issued a notice to investors who purchased Unicycive Therapeutics securities between December 29, 2025, and June 29, 2026. The firm is organizing a class-action lawsuit alleging that the company provided misleading information to the market.
The complaint centers on whether the company failed to disclose critical information, which plaintiffs claim artificially inflated the share price during the class period. Such litigation often arises when market performance deviates significantly from public disclosures provided by management.
Investors wishing to serve as lead plaintiffs must file their applications by the November deadline. The lawsuit remains in the preliminary stages as the court reviews the claims against the company.